pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
209
stories
3h
STAT+: Up and down the ladder: The latest comings and goings
stat
3h
STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
stat
1d
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
1d
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
2d
STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and more
stat
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
3d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
3d
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
stat
3d
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
fiercebiotech
3d
STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
stat
4d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
4d
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
endpoints
4d
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
stat
4d
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
stat
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca cans late-stage volrustomig trial after lung cancer setback
endpoints
4d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
7d
ICER says AstraZeneca’s new blood pressure med isn’t cost-effective
endpoints
7d
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
7d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
Biotech initiatives pick up as more regions race to become hubs
biopharma dive
8d
New Taiho, Cullinan data heats up lung cancer drug battle
biopharma dive
8d
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
8d
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
fiercebiotech
8d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
9d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
10d
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
10d
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
fiercebiotech
11d
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
biospace
← prev
page 1 of 7
next →
